1. Naturally occurring compounds elicit HIV-1 replication in chronically infected promonocytic cells.
- Author
-
Barquero AA, Dávola ME, Riva DA, Mersich SE, and Alché LE
- Subjects
- Cell Line, Cell Line, Tumor, Cholestanones pharmacology, Curcumin pharmacology, DNA Replication drug effects, HIV Infections metabolism, Humans, Interleukin-6 pharmacology, Limonins pharmacology, Masoprocol pharmacology, Monocytes metabolism, Plant Extracts pharmacology, Reactive Oxygen Species metabolism, Stigmasterol analogs & derivatives, Stigmasterol pharmacology, Tumor Necrosis Factor-alpha metabolism, U937 Cells, Biological Factors pharmacology, HIV Infections virology, HIV-1 drug effects, Monocytes virology, Virus Replication drug effects
- Abstract
Since antiretroviral therapy suppresses but does not eradicate HIV-1 infection, methods to purge viral reservoirs are required. Many strategies involve the reactivation of chronically HIV infected cells to induce the expression of integrated viral genome. In this study, five bioactive compounds, the plant derivatives 1-cinnamoyl-3,11-dihydroxymeliacarpin (CDM), nordihydroguaiaretic acid (NDGA), and curcumin (Cur) and the synthetic stigmasterol analogs (22S,23S)-22,23-dihydroxystigmast-4-en-3-one (compound 1) and (22S,23S)-3 β -bromo-5 α ,22,23-trihydroxystigmastan-6-one (compound 2), were evaluated for their ability to elicit HIV replication in promonocytic (U1) and lymphocytic (H9+) HIV-1 chronically infected cells. The results revealed that natural compounds CDM, NDGA, and Cur were able to increase HIV-1 p24 antigen, determined by ELISA, only in latently infected promonocytic cells. CDM would reactivate HIV from latency by modulating the release of IL-6 and TNF- α , since the amount of both cytokines measured through ELISA significantly increased in U1 treated cells. Besides, NDGA increased ROS production, which might be related to the increase on p24 level observed in NDGA treated U1. These findings suggest that CDM, NDGA, and Cur might be candidates for further studies on latency-reversing therapeutics to eliminate latently HIV-1 reservoirs.
- Published
- 2014
- Full Text
- View/download PDF